Kumar, S., Kaufman, J. L., Mikhael, J., Gasparetto, C., Vij, R., Pegourie, B., … Touzeau, C. (2017). Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma. In Clinical Lymphoma Myeloma and Leukemia (Vol. 17, pp. e27–e27). Elsevier BV. https://doi.org/10.1016/j.clml.2017.03.046

Kumar, Shaji, Jonathan L. Kaufman, Joseph Mikhael, Cristina Gasparetto, Ravi Vij, Brigitte Pegourie, Lofti Benboubker, et al. “Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma.” In Clinical Lymphoma Myeloma and Leukemia, 17:e27–e27. Elsevier BV, 2017. https://doi.org/10.1016/j.clml.2017.03.046.

Kumar S, Kaufman JL, Mikhael J, Gasparetto C, Vij R, Pegourie B, et al. Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2017. p. e27–e27.

Kumar, Shaji, et al. “Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma.” Clinical Lymphoma Myeloma and Leukemia, vol. 17, no. 1, Elsevier BV, 2017, pp. e27–e27. Crossref, doi:10.1016/j.clml.2017.03.046.

Kumar S, Kaufman JL, Mikhael J, Gasparetto C, Vij R, Pegourie B, Benboubker L, Facon T, Moreau P, Amiot M, Alzate S, Dunbar M, Xu T, Agarwal S, Leverson J, Ross J, Maciag P, Verdugo M, Touzeau C. Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2017. p. e27–e27.